在体内，HDC1抑制剂SAHA与阿霉素的组合具有三阴性乳腺癌的协同疗效。
The combination of the HDC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo.
发表日期：2023 Sep 14
作者：
Yuheng Pang, Runze Shi, Liujia Chan, Yu Lu, Di Zhu, Tong Liu, Meisi Yan, Yuji Wang, Wenjing Wang
来源：
Epigenetics & Chromatin
摘要：
Vorinostat（SAHA）是一种通过表观遗传调控发挥作用的组蛋白去乙酰化酶抑制剂。具体而言，SAHA可以单独或与其他化学治疗药物联合抑制三阴性乳腺癌（TNBC）细胞的增殖。多柔比星（DOX）是一种传统的化学治疗药物，它在抑制癌细胞增殖的同时，还会引起强烈的毒性效应。在本研究中，我们调查了这两种药物联合应用在抗TNBC方面的协同潜力。我们的结果表明，这两种药物的联合应用能够增强对癌细胞增殖的抑制效果，导致细胞有丝分裂期的改变，以及对癌细胞干细胞性质的抑制。此外，我们的体内研究揭示了当SAHA与DOX联合应用时，它不仅对肿瘤转移具有抑制作用，还在调节肿瘤内的免疫微环境方面发挥作用。总的来说，DOX和SAHA的联合应用在TNBC背景下呈现出一条有前景的创新联合化疗途径。版权所有 © 2023 Elsevier Ltd.
Vorinostat (SAHA) is a histone deacetylase inhibitor that exerts its effects through epigenetic regulation. Specifically, SAHA can inhibit the proliferation of triple-negative breast cancer (TNBC) cells alone or in combination with other chemotherapeutic agents. Doxorubicin (DOX), a traditional chemotherapeutic drug, exhibits a potent cytotoxic effect on cancer cells while also inducing strong toxic effects. In this study, we investigated the synergistic potential of these two drugs in combination against TNBC. Our results suggested that the combination of these two drugs could enhance the inhibitory effect on cancer cell proliferation, resulting in alterations in cell mitotic phase, and suppression of cancer cell stemness. Moreover, our in vivo study unveiled that when SAHA was combined with DOX, it not only exhibited an inhibitory effect on tumor metastasis but also played a role in regulating the immune microenvironment within tumors. Overall, the combination of DOX and SAHA presents a promising avenue for innovative combination chemotherapy in the context of TNBC.Copyright © 2023. Published by Elsevier Ltd.